• About
  • Policies
  • What is open access
  • Library
  • Contact
Advanced search
      View Item 
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      •   BUIR Home
      • Scholarly Publications
      • Faculty of Science
      • Department of Molecular Biology and Genetics
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.

      Renin angiotensin system genes are biomarkers for personalized treatment of acute myeloid leukemia with Doxorubicin as well as etoposide

      Thumbnail
      View / Download
      1.4 Mb
      Author(s)
      Türk, S.
      Türk, C.
      Akbar, Muhammad Waqas
      Küçükkaraduman, Barış
      İşbilen, Murat
      Demirkol-Canlı, S.
      Malkan, Ü. Y.
      Okay, M.
      Uçar, G.
      Sayınalp, N.
      Haznedaroğlu, İ. C.
      Güre, Ali Osmay
      Date
      2020
      Source Title
      PLoS ONE
      Print ISSN
      1932-6203
      Publisher
      Public Library of Science
      Volume
      15
      Issue
      November
      Pages
      1 - 17
      Language
      English
      Type
      Article
      Item Usage Stats
      67
      views
      33
      downloads
      Abstract
      Despite the availability of various treatment protocols, response to therapy in patients with Acute Myeloid Leukemia (AML) remains largely unpredictable. Transcriptomic profiling studies have thus far revealed the presence of molecular subtypes of AML that are not accounted for by standard clinical parameters or by routinely used biomarkers. Such molecular subtypes of AML are predicted to vary in response to chemotherapy or targeted therapy. The Renin-Angiotensin System (RAS) is an important group of proteins that play a critical role in regulating blood pressure, vascular resistance and fluid/electrolyte balance. RAS pathway genes are also known to be present locally in tissues such as the bone marrow, where they play an important role in leukemic hematopoiesis. In this study, we asked if the RAS genes could be utilized to predict drug responses in patients with AML. We show that the combined in silico analysis of up to five RAS genes can reliably predict sensitivity to Doxorubicin as well as Etoposide in AML. The same genes could also predict sensitivity to Doxorubicin when tested in vitro. Additionally, gene set enrichment analysis revealed enrichment of TNF-alpha and type-I IFN response genes among sensitive, and TGF-beta and fibronectin related genes in resistant cancer cells. However, this does not seem to reflect an epithelial to mesenchymal transition per se. We also identified that RAS genes can stratify patients with AML into subtypes with distinct prognosis. Together, our results demonstrate that genes present in RAS are biomarkers for drug sensitivity and the prognostication of AML.
      Keywords
      Gene expression
      Linear regression analysis
      Renin-angiotensin system
      Acute myeloid leukemia
      Cytotoxicity
      Cancer drug discovery
      Prognosis
      Biomarkers
      Permalink
      http://hdl.handle.net/11693/75676
      Published Version (Please cite this version)
      https://dx.doi.org/10.1371/journal.pone.0242497
      Collections
      • Department of Molecular Biology and Genetics 512
      Show full item record

      Browse

      All of BUIRCommunities & CollectionsTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCoursesThis CollectionTitlesAuthorsAdvisorsBy Issue DateKeywordsTypeDepartmentsCourses

      My Account

      Login

      Statistics

      View Usage StatisticsView Google Analytics Statistics

      Bilkent University

      If you have trouble accessing this page and need to request an alternate format, contact the site administrator. Phone: (312) 290 2976
      © Bilkent University - Library IT

      Contact Us | Send Feedback | Off-Campus Access | Admin | Privacy